How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?

How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?Подробнее

Risk factors to predict post-CD19 CAR-T cell therapy outcomes in patients with LBCLПодробнее

Cardio-Oncology A-Z: CAR-T Cell Cardiotoxicity With Dr Daniel ChenПодробнее

Factors associated with treatment response to CD19 CAR T-cell therapy in B-ALLПодробнее

CD19 Targeted CAR T-cell Therapy in LBCLПодробнее

Evaluating post-infusion CAR-Treg cells to identify patients resistant to CD19 CAR-T therapyПодробнее

CAR-T Therapy: A Burgeoning New Cancer Treatment -- Natan Kraitman, MDПодробнее

Dr. Shah on Differences Between Anti–CD19 CAR T-Cell TherapiesПодробнее

Outcomes and management of patients who develop COVID-19 after CD19-targeted CAR-T therapyПодробнее

Cardiac Complications of Emerging Cancer TherapeuticsПодробнее

Clinical data for CD19-directed CAR T-cell products in ALLПодробнее

Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignanciesПодробнее

A Look at How CAR-T Cell Therapy WorksПодробнее

Outcomes for patients with disease progression following CD19-specific CAR T-cell therapyПодробнее

Engineering T Cells for Cancer - Carl JuneПодробнее

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s ExperienceПодробнее

Phase I study of CD22-targeted CAR-T therapy in patients with CD19-negative B-ALLПодробнее

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignanciesПодробнее

A Look at How CAR-T Cell Therapy WorksПодробнее

Key questions in the field of CD19 CAR T-cell therapyПодробнее